Insider Transactions in Q2 2023 at Catalyst Pharmaceuticals, Inc. (CPRX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2023
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,942
-22.47%
|
-
|
|
Jun 27
2023
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.31%
|
-
|
|
May 16
2023
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
173,849
+4.05%
|
$0
$0.79 P/Share
|
|
May 15
2023
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
26,151
-0.66%
|
$339,963
$13.23 P/Share
|
|
May 15
2023
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,151
+0.65%
|
$0
$0.79 P/Share
|
|
May 12
2023
|
Richard J Daly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+25.25%
|
$0
$0.79 P/Share
|
|
May 11
2023
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+12.7%
|
$0
$0.79 P/Share
|
|
May 11
2023
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+5.66%
|
$0
$0.79 P/Share
|
|
May 04
2023
|
Philip H Coelho Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+19.62%
|
$0
$0.79 P/Share
|
|
Apr 05
2023
|
David S Tierney Director |
SELL
Open market or private sale
|
Direct |
30,000
-8.73%
|
$480,000
$16.83 P/Share
|
|
Apr 05
2023
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+8.03%
|
$0
$0.79 P/Share
|